Page 892«..1020..891892893894..900910..»

Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. – UroToday

Posted: September 29, 2020 at 6:56 am

Urothelial carcinoma of the bladder (UCB) exhibits significant sexual dimorphism in the incidence, etiology, and response to intravesical immunotherapy. Environmental factors such as tobacco use and clinical management issues such as delayed presentation have widely been associated with sex differences in UCB outcomes. Emerging findings from immune checkpoint blockade trials are suggestive of differential outcomes in females compared with males. Sex-specific differences in the way immune system functions and responds to pathogenic insults are well established. As such, an in-depth understanding of the genetic and epigenetic factors contributing to sex-associated differences in response to immunomodulatory therapies is needed urgently for improved management of UCB.

To review the associations between patient sex and clinical outcomes, with a focus on the incidence, host intrinsic features, and response to therapies in UCB.

Using the PubMed database, this narrative review evaluates published findings from mouse model-based and clinical cohort studies to identify factors associated with sex and clinical outcomes in bladder cancer. A scoping review of the key findings on epidemiology, genetic, hormonal, immune physiology, and clinical outcomes was performed to explore potential factors that could have implications in immunomodulatory therapy design.

Sex-associated differences in UCB incidence and clinical outcomes are influenced by sex hormones, local bladder resident immune populations, tumor genetics, and bladder microbiome. In the context of therapeutic outcomes, sex differences are prominent in response to bacillus Calmette-Gurin immunotherapy used in the treatment of non-muscle-invasive bladder cancer. Similarly, with respect to tumor molecular profiles in muscle-invasive bladder cancer, tumors from females show enrichment of the basal subtype.

Among proposed tumor/host intrinsic factors that may influence response to immune-based therapies, patient sex remains a challenging consideration that deserves further attention. Evidence to date supports a multifactorial origin of sexual dimorphism in the incidence and outcomes of UCB.

In this review, we highlight the sex-associated host and tumor intrinsic features that may potentially drive differential disease progression and therapeutic response in urothelial carcinoma of the bladder.

European urology oncology. 2020 Sep 20 [Epub ahead of print]

Madhuri Koti, Molly A Ingersoll, Shilpa Gupta, Christa M Lam, Xue Li, Ashish M Kamat, Peter C Black, D Robert Siemens

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada; Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada; Cancer Biology and Genetics Division, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada; Department of Urology, Queen's University, Kingston, Ontario, Canada. Electronic address: ., Department of Immunology, Institut Pasteur, Paris, France., Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Department of Urology and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Department of Urology, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Department of Urology, Queen's University, Kingston, Ontario, Canada.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/32967818

Continued here:
Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. - UroToday

Posted in Molecular Genetics | Comments Off on Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. – UroToday

ONLINE: The Future of Medicine – Isthmus

Posted: September 29, 2020 at 6:56 am

Watch here: https://www.youtube.com/watch?feature=youtu.be&v=VVkQU91KbEs

press release: The UW has a long history of pioneering medical advancements that have transformed the world. From performing the first bone marrow transplant in the United States to cultivating the first laboratory-derived human embryonic stem cells. Now, where will UW medical research go next?

On the next Wisconsin Medicine Livestream, meet trailblazing doctors, researchers, and medical leaders who are charting a bold course to completely alter the health care landscape. During this insightful panel discussion, well explore how gene therapy and cell replacements could hold the keys to treating inherited and acquired blindness. Youll also discover the remarkable potential in xenotransplantation where nonhuman animal source organs are transplanted into human recipients. In addition, you will learn about UW Healths journey to build a multidisciplinary program to serve the community. These, and other, fascinating developments in treatment and care are happening right now at the UW and are the future of medicine. The presentation will be moderated by Robert Golden, the dean of the University of WisconsinMadisons School of Medicine and Public Health.

Our Guests:

David Gamm, professor, Department of Ophthalmology and Visual Sciences; Emmett A. Humble Distinguished Director, McPherson Eye Research Institute; Sandra Lemke Trout Chair in Eye Research

Dr. Gamms lab is at the forefront in developing cell-based therapies to combat retinal degenerative diseases (RDDs). As the director of the McPherson Eye Research Institute and a member of the Waisman Center Stem Cell Research Program, the UW Stem Cell and Regenerative Medicine Center, and the American Society for Clinical Investigation, his efforts are directed toward basic and translational retinal stem cell research. The Gamm Lab uses induced pluripotent stem cells to create retinal tissues composed of authentic human photoreceptor cells rods and cones that can detect light and initiate visual signals in a dish. The aims of his laboratory are to investigate the cellular and molecular events that occur during human retinal development and to generate cells for use in retinal disease modeling and cell replacement therapies. In collaboration with other researchers at UWMadison and around the world, the lab is developing methods to produce and transplant photoreceptors and/or retinal pigment epithelium (RPE) in preparation for future clinical trials. At the same time, the Gamm Lab uses lab-grown photoreceptor and RPE cells to test and advance a host of other experimental treatments, including gene therapies. In so doing, the lab seeks to delay or reverse the effects of blinding disorders, such as retinitis pigmentosa and age-related macular degeneration, and to develop or codevelop effective interventions for these RDDs at all stages of disease.

Dhanansayan Shanmuganayagam, assistant professor, Department of Surgery, School of Medicine and Public Health; Department of Animal and Dairy Sciences, UWMadison; director, Biomedical, and Genomic Research Group

Dr. Shanmuganayagams research focuses on the development and utilization of pigs as homologous models to close the translational gap in human disease research, taking advantage of the overwhelming similarities between pigs and humans in terms of genetics, anatomy, physiology, and immunology. He and his colleagues created the human-sized Wisconsin Miniature Swine breed that is unique to the university. The breed exhibits greater physiological similarity to humans, particularly in vascular biology and in modeling metabolic disorders and obesity. He currently leads genetic engineering of swine at the UW. His team has created more than 15 genetic porcine models including several of pediatric genetic cancer-predisposition disorders such as neurofibromatosis type 1 (NF1). In the context of NF1, his lab is studying the role of alternative splicing of the nf1 gene on the tissue-specific function of neurofibromin and whether gene therapy to modulate the regulation of this splicing can be used as a viable treatment strategy for children with the disorder.

Dr. Shanmuganayagam is also currently leading the efforts to establish the University of Wisconsin Center for Biomedical Swine Research and Innovation (CBSRI) that will leverage the translatability of research in pig models and UWMadisons unique swine and biomedical research infrastructure, resources, and expertise to conduct innovative basic and translational research on human diseases. The central mission of CBSRI is to innovate and accelerate the discovery and development of clinically relevant therapies and technologies. The center will also serve to innovate graduate and medical training. As the only center of its kind in the United States, CBSRI will make UWMadison a hub of translational research and industry-partnered biomedical innovation.

Petros Anagnostopoulos, surgeon in chief, American Family Childrens Hospital; chief, Section of Pediatric Cardiothoracic Surgery; professor, Department of Surgery, Division of Cardiothoracic Surgery

Dr. Anagnostopoulos is certified by the American Board of Thoracic Surgery and the American Board of Surgery. He completed two fellowships, one in cardiothoracic surgery at the University of Pittsburgh School of Medicine and a second in pediatric cardiac surgery at the University of California, San Francisco School of Medicine. He completed his general surgery residency at Henry Ford Hospital in Detroit. Dr. Anagnostopoulos received his MD from the University of Athens Medical School, Greece. His clinical interests include pediatric congenital heart surgery and minimally invasive heart surgery.

Dr. Anagnostopoulos specializes in complex neonatal and infant cardiac reconstructive surgery, pediatric heart surgery, adult congenital cardiac surgery, single ventricle palliation, extracorporeal life support, extracorporeal membrane oxygenation, ventricular assist devices, minimally invasive cardiac surgery, hybrid surgical-catheterization cardiac surgery, off-pump cardiac surgery, complex mitral and tricuspid valve repair, aortic root surgery, tetralogy of Fallot, coronary artery anomalies, Ross operations, obstructive cardiomyopathy, and heart transplantation.

When: Tuesday, Sept. 29, at 7 p.m. CDT

Where: Wisconsin Medicine Livestream: wiscmedicine.org/programs/ending-alzheimers

Excerpt from:
ONLINE: The Future of Medicine - Isthmus

Posted in Molecular Genetics | Comments Off on ONLINE: The Future of Medicine – Isthmus

MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2…

Posted: September 29, 2020 at 6:56 am

LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice.

A mouse model study was conducted to assess systemic IgG and mucosal IgA antibody production against S1 Ag after intranasal vaccination with MediciNova’s BC-PIV SARS-CoV-2 vaccine prototype. We confirmed a high IgA antibody titer against S1 Ag in the nasal lavage fluid from mice given intranasal BC-PIV SARS-CoV-2 vaccine. We also confirmed that a high IgG antibody titer against S1 Ag was induced in mice serum.

Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, "We are very encouraged that our intranasal BC-PIV SARS-CoV-2 vaccine induced high titers of systemic serum IgG and mucosal IgA neutralizing antibodies in a mouse model study. These successful results support the scientific and technical rationale of our intranasal vaccine in addition to similar success with BioComo’s BC-PIV RSV vaccine prototype. We look forward to reporting additional progress on our intranasal COVID-19 vaccine in the near future.”

About the BC-PIV SARS-CoV-2 V accine for COVID-19

BC-PIV, an innovative non-transmissible viral vector co-developed by BioComo and Mie University, is derived from the recombinant human parainfluenza virus type 2 (hPIV2). It is highly efficient in its ability to transfer multiple foreign proteins to recipients and has a strong safety profile as no secondary infectious virus is produced. BC-PIV is designed to display not only the gene but also the foreign protein itself on the surface and inside of the viral membrane. Therefore, it can carry the large membrane proteins of viruses and signal transduction receptors/ligand proteins on the viral surface. BC-PIV is able to carry the proteins that require a proper three-dimensional structure or multimeric structure while maintaining the structure. BC-PIV elicits good immunogenicity against antigen proteins without adjuvants. The BC-PIV SARS-CoV-2 vaccine prototype has been developed to include the specific SARS-CoV-2 antigen protein in order to express maximum antigenicity. The BC-PIV SARS-COV-2 vaccine can be developed as an intranasal vaccine in addition to an intramuscular injection because of its high affinity to nasal and upper respiratory tract mucosa, which is the same route of the natural infection of SARS-CoV-2. An intranasal vaccine is expected to induce local mucosal immunity. To date, BioComo has succeeded in producing a recombinant Ebola virus vaccine ( https://www.nature.com/articles/s41598-019-49579-y ) and a Respiratory Syncytial virus prefusion F vaccine (unpublished data) using this BC-PIV platform technology.

About BioComo

BioComo, a biotech company founded at Mie Prefecture Japan in May 2008, is developing cutting-edge technology platforms for creating the novel and predominant vaccine carriers and adjuvants to enhance immunity in collaboration with the Microbiology and Molecular Genetics Department of Mie University. They have already succeeded in the development of a highly efficacious and state-of-the art vaccine carrier and novel adjuvant candidates. Their technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, Influenza virus, and SARS-CoV-2. It will also enable faster and more cost-effective production of those vaccines. BC-PIV is the core platform technology which carries the corporate namesake, BioComo, and the leading vaccine carrier that is derived from the recombinant human parainfluenza virus 2 (hPIV2) vectors. BioComo is dedicated to inventing new vaccines for both global infection threats as well as malignant tumors.

About MediciNova MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova's current strategy is to focus on BC-PIV SARS-COV-2 vaccine for COVID-19, MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma, as well as prevention of acute respiratory distress syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit http://www.medicinova.com .

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of BC-PIV SARS-COV-2 vaccine , MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," considering,” planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of BC-PIV SARS-COV-2 vaccine , MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

INVESTOR CONTACT: Geoff O'Brien Vice President MediciNova, Inc. info@medicinova.com

Originally posted here:
MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2...

Posted in Molecular Genetics | Comments Off on MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2…

Get Up to Speed On the State of Eco-Fashion – NEO.LIFE

Posted: September 27, 2020 at 4:58 am

In December 2019, an odd new product hit the headlines. Called FLWRDWN, unlike every other fashion material innovation youve read about that always seem to be years out of reach, the mixture of waste wildflowers, biopolymer, and a patented cellulosic aerogel debuted to the world ready to be worn, encased inside a fashionable nylon puffer coat.

Fashion drops are usually 99.9% hype. But FLWRDWN, which garnered press mentions from Vogue to Wired UK, arguably deserved more. It is natural, plant-based, animal-free, fossil-fuel free, fluffy, and warm. It is a seemingly perfect replacement for what you usually find in puffers: goose down if youre a traditionalist or, if you are the kind to worry about feathers being ripped out of live geese, polyester fill.

FLWRDWN may have solved for the fact that so-called conscious fashion consumers usually have to choose between two unsatisfying modalities: biodegradable natural materials that hurt animals and the environment, or cruelty-free synthetic fabrics that will stick around on Earth until the sun burns out.

Enter the biotech industry, which is racing to grow nature-inspired textiles, leathers, and dyes in the lab. These innovations would supposedly combine the best of both worlds: made-to-order and efficient factory production with plant-based ingredients. The question then becomes: can you actually commercialize these materials to make a tangible difference?

So called natural, i.e., traditional, materialssuch as down, leather, and cottonfeel more eco-friendly, but come with a whole host of messy human, animal, and environmental issues. The alternativesynthetic fibers like nylon, acrylic, polyester, and vegan leathers like polyurethane and PVCare equally if not more reviled by tree-hugging fashionistas. Made from fossil fuels, theyll biodegrade as quickly as any plastic, which is, for all intents and purposes, never.

Fashion brands are tired of being dragged into these very unglamorous and ugly conversations about animal cruelty and toxic chemicals, and they would like to find a solution. The race is on to create a library of carbon-neutral, recyclable, biodegradable, and relatively affordable materials that mimic natures cyclical material flows and diversity, and to produce them in quantities large enough to satisfy the appetites of 8 billion consumers.

For all its trend chasing, until now the fashion industry has been notoriously averse to technological innovation. In the tech industry, you always have companies that are looking two years, five years, 10 years ahead, at what the next product would be and designing the needs of their own production, says Amanda Parkes, the chief innovation officer for Pangaia, the fashion startup behind FLWRDWN. Parkes has worked as a science museum curator, has been a structural engineer for couture fashion, studied wearable tech at MIT, and founded an algae biofuels startup. In other words, she is well qualified to lead fashion into the future. There hasnt been a lot of internal R&D inherent to big fashion brands, she says.

Not so anymore. H&M, as one of the worlds largest fashion brands, has been taking heat for contributing to the 92 million tons (and rising) of fashion that we collectively send to landfills, incinerators, and oceans every year. Sustainable fashion advocates will tell you we should just buy less stuff (which, were doing right now with, uh, mixed results) but the fast-fashion brand has taken a different approach: throwing money at almost every fabric innovation on the market. Its invested in several material tech startups (including Colorifix, Worn Again, Renewcell, Ambercycle, and Infinited Fiber) and promotes the materials in its glossy Conscious Exclusive capsule collections.

H&Ms Global Change Award winner page can sometimes read like the inventory of an eclectic compost bin.

As a small and scrappy material technology startup and fashion brand, Pangaia has a different, more holistic approach. It researches the most sustainable materials currently on the market and comes up with patented technology to fill the holes. It hosts a direct-to-consumer online shop filled with sleek streetwear, including tees from its other famous release, Seaweed Fiber. But it also collaborates with the rest of the industry, selling materials to other brands, connecting startups to manufacturers, and helping smart but nerdy textiles scientists talk to fashion lovers about their product. It seems to be working: since FLWRDWN was released, Pangaias Instagram following has grown from 10,000 to 500,000, and Parkes says there are some exciting new product drops coming this fall.

H&Ms annual Global Change Award winner page can sometimes read like an inventory of a truly eclectic compost bin: Orange peels, seaweed, grape waste, cow manure, mushrooms, wheat, Peruvian fruit, and nettles, have all shown up in prize-winning materials. Other crops that have had their five minutes of fame in the fashion world include pineapple leaves, sugarcane, soybeans, apple waste, winemaking waste, cactus, yeast, and coconut fiber.

But the big question is this: Will any of these material innovations actually solve our planetary problems?

The two words on everyones lips right now when it comes to fashion innovation are lab-grown: lab-grown leather, lab-grown silk, and lab-grown cotton. These arent faux materials, but the real thing produced either by growing stem cells, in the case of cotton, or genetically engineering yeast to eat sugar and spit out collagen or silk proteins. These startups, and the resulting headlines, talk in the present tense, even though its anyones guess when well be able to wear any of it.

Both the fashion and tech world tend to be too impatient about the time it will take for the science to come to fruition. After enduring the avalanche of inquiries that follow on the heels of breathless hype in fashion magazines, vegan blogs, and business publications (guilty), the researchers retreat to their labs for years to disentangle all the knots in the new science, while the startups try to find enough money to build an entirely new supply chain to produce their productswhich dont even exist yetat scale.

It can sometimes feel like an endless fashion show of prototypes well never get to buy. Bolt Threads, for example, collaborated with the luxury, cruelty-free fashion brand Stella McCartney in 2017 on a cocktail dress made from its lab-grown silk. Bolt Threads has engineered yeast to eat sugar and spit out silk proteins, which are isolated then spun into what the startup calls Microsilk. The sell is that traditional silk spinning requires boiling silkworms alive, and purportedly has high energy and water usagethe highest by far of any textile, in fact.

Because of the great press about Microsilk, in late 2017 Bolt Threads raised $123 million and then licensed technology to grow mushroom leather from the New York startup Ecovativ. The technology, called Mylo, is made by growing mycelium, the root network of mushrooms, into a sheet that is then tanned like real leather. They debuted a prototype of a mushroom leather bag in early 2018 with Stella McCartney, and later that year launched a Kickstarter for a tote bag made of mushroom leather. However, consumers have yet to see either product up close. The promised tote bags delivery has been pushed back several times to late 2020partly due to COVID-19, the company saysand weve heard nothing of microsilk since Adidas and Stella McCartney collaborated on a tennis dress in 2019.

Modern Meadow, another exciting startup that engineers yeast to spit out collagen for lab-grown leather they call Zoa, also blew past an expected commercial launch date of 2018. They have since had their heads down working in their Brooklyn lab, avoiding press. An investor for lab-grown leather competitor MycoWorks got in a dig at Modern Meadow in a February essay explaining his investment. Dont get me wrong, Modern Meadow has an incredible team, he wrote. [CEO] Andras Forgacs is as smart as they come, and I expect theyll get there; but harnessing biology is a really really hard problem.

The investor is right: Were talking about designing and manipulating biomolecules and proteins to create an entirely new material the world has never seen before, eliminating animals and the farm entirely while also satisfying the fussy designers at luxury brands, and then building an entirely new supply chain. And not everyone is comfortable with a world where we are genetically engineering silk and leather in a lab. A joint report by the California nonprofit Fibershed and the Canadian nonprofit ETC Group warned that lab-grown textiles could undermine farmers worldwide, create a dangerous new source of biotech waste, put additional pressure on ecosystems, and divert support away from truly sustainable natural fiber economies.

They may be relieved that all signs point to Reishi by MycoWorks winning the race for commercially available, petroleum-free leather. Reishi is also made by growing mycelium, which feeds on agricultural waste such as sawdust in two-by-three foot trays in a dimly lit, low-energy facility before being sent off to a heritage tannery in Spain for finishing. A chief manufacturing officer and chief of product joined the startup in June, and CEO Matthew Scullin says the company actually added brands to its customer roster during the pandemic and is in the process of opening a third commercial plant with a production capacity of 80,000 square feet of material per year. Scullin unfortunately couldnt share any details about the luxury products designer clients are launching with MycoWorks, except that they are slated for the next few months. Vague, but promising.

Agricultural waste alone could provide 2.5 times the material we need to meet global fiber demand.

Before you start dreaming about a world in which the Amazon rainforest is no longer burned for cattle ranching, we must point out that there will be zero practical effect on the leather industry if we replace the real stuff with its lab-grown or mushroom equivalents. Even before fashions appetite for leather plummeted, a cattle rancher would earn less than 8% of his income from selling the hideits always been just a bonus. At the same time, the global demand for beef is rising. The result is a huge glut of cow hides, which go to the landfill or are burned. As long as were eating more steaks than we are wearing cowboy boots, we may as well put that leather to use.

Still, there are definitely some environmental benefits to lab-grown leather aside from the absence of a slaughterhouse. Because it can be grown into custom shapes, it doesnt produce off-cut waste like irregularly shaped cow hides. It also skips right over the step used for real leather, in which chemicals help scrape fat and hair off, creating a noxious waste; MycoWorks process uses benign, chromium-free chemistry. And the process of growing mycelium actually draws carbon down from the atmosphere instead of emitting it.

Newcomer Galy is a startup that grows cotton fiber in a dish. Using the plants stem cellswhich can be coaxed to become any part of the plantGaly is able to grow just the fiber in their lab. Galy claims their lab-grown cotton grows 10 times faster than field-grown cotton, using a fraction of the land and water typically needed, emitting a fraction of emissions, and with no pesticides. They emerged from stealth mode this year to win H&Ms Global Change Award, and garnered a $500,000 investment from Agronomics, a venture capital firm that mainly focuses on biotech meat replacements.

Unsurprisingly, these lab-grown materials will be in the premium category when they do come out, meaning their uptake by the notoriously price conscious mass-market fashion industry will be low. For now, anyway.

While we wait for fashion from a beaker, here are new biotech materials that we can shop now.

Renewcell in Sweden, Evrnu in Seattle, and Infinited Fiber in Finland use cotton waste and nontoxic chemicals to create new, cotton-like fibers. Levis launched its first batch of jeans made with 20% Circulose, Renewcells product, in July this year and probably would have made a bigger splash were it not for the pandemic. So far, the products from Adidas, Stella McCartney, and Levis that use Evrnus technology, NuCycl, have been prototypes. That could change soon with the $9.1 million Series A investment it closed last year.

Increasingly, entrepreneurs are looking to mine the worlds agricultural waste which, according to the Biomimicry Institute, could alone provide 2.5 times the material we need to meet global fiber demand. Orange Fiber is the name of both an Italian startup and its product, a silky acetate made from the waste generated by Sicilys orange juice industry. It was featured in a jacquard print, off-the-shoulder top in H&Ms small 2019 Conscious Exclusive Collection, but since then the company has gone quiet. Agraloop has ditched chemicals completely for a secret physical process that turns agricultural waste into a linen-like material, and has hinted at its own 2020 H&M launch.

Then there are what you could call the food leathers. Theres grape waste leather by Vegea, which has been used in H&Ms Conscious Exclusive collection, some luxury Italian brands, and a Bentley concept car. Theres Apple Leather from Frumat, made from harvest waste that you can find in some quite nice fall boots; Desserto cactus leather, which went quiet after releasing a truly memorable promotional video; and the industrys favorite, Piatex by Ananas Anam, made from pineapple-leaf fiber, which you can find in everything from sandals and watch straps to leather jackets and journal covers. Unfortunately, all of the above vegan leathers use synthetic finishes and binders, so arent entirely fossil fuel free or biodegradable. Theyre likely stopgap measures on our way to 100% plant-based and lab-grown materials, and appeal mainly to resolute vegans, rather than eco-warriors.

Theres one truly plant-based leather on the horizon, and that is Mirum by Illinois-based Natural Fiber Welding. They take fibrous materials like waste cork, hemp, coconut, cotton, and vegetable oil to create biodegradable composites that are pressed into the shape and grain of leather. Founder Luke Haverhals, who discovered the chemistry while at the Naval Academy, says Mirum is close to carbon neutral and can be recycled in the same facility in which it was made. Ralph Lauren took a minority stake in Natural Fiber Welding in August to help it scale its materialsyou should be able to buy a Mirum wallet or shoes by mid-2021.

The huge missing piece in all of this very exciting news is the data proving that these materials are sustainable. Its hard to measure the footprint of your product until your material mix is set and your factory is pretty much up to speed. But large brands, which have been publicly committing to science-based targets around climate change, are starting to demand receipts.

In that regard, Algix, which creates an algae-infused EVA foam called Bloom, has a market advantage. It sources algae from projects that filter out algae blooms from lakes, plasticizes it, mixes it with regular petroleum-based EVA or TPE to get it up to performance, and then ships the resulting pellets to Asian manufacturers who produce for footwear brands including Vivobarefoot, Adidas, Dr. Scholls, Aldo, Billabong, and Red Wing.

While Algixs data hasnt been publicly released yet, founder Ryan Hunt says that 1.4 kilograms of CO2-equivalent greenhouse gases are released for every kilogram of Bloom manufactured, less than half of regular EVA. The algae itself is carbon negative and regenerative; Hunt says that the algae in one kilogram of Bloom has filtered 2,200 liters of water. (For context, one kilogram of cotton requires on average 1,200 liters of irrigation water.)

Blooms petroleum-based EVA content means it wont biodegrade, but when its literally locked up carbon and water pollutants inside your shoes, that almost feels besides the point. Brands have been banging on the regenerative drum in recent months, and Bloom slots right into those plans. I believe the reason that we have received such rapid adoption in the footwear space is because we have done all the homework and were a group of scientists, says Hunt, who has a background in physics and engineering. The brands view us as a sustainable ingredient that can help quantify the environmental improvements.

But Bloom alone wont be the solution. Neither will mushroom leather, or lab-grown cotton, or linen made from agricultural waste. But it could be all of them, together, with some room still left for smallholder farmers to grow and raise traditional materials the right way: regeneratively.

People used to ask me this when I worked on fashion and wearables, says Parkes, Pangaias chief innovation officer. Whos gonna win? Whos gonna become the Apple? The way that you win is to have everything work together in balance. Its a lot harder to do, but its totally necessary for us to have a system that mimics nature.

The rest is here:
Get Up to Speed On the State of Eco-Fashion - NEO.LIFE

Posted in Illinois Stem Cells | Comments Off on Get Up to Speed On the State of Eco-Fashion – NEO.LIFE

The science and medicine of human immunology – Science Magazine

Posted: September 27, 2020 at 4:53 am

Immunology through a human lens

The coronavirus disease 2019 (COVID-19) pandemic has underscored the critical need to better understand the human immune system and how to unleash its power to develop vaccines and therapeutics. Much of our knowledge of the immune system has accrued from studies in mice, yet vaccines and drugs that work effectively in mice do not always translate into humans. Pulendran and Davis review recent technological advances that have facilitated the study of the immune system in humans. They discuss new insights and how these can affect the development of drugs and vaccines in the modern era.

Science, this issue p. eaay4014

The mammalian immune system is a remarkable sensory system for the detection and neutralization of pathogens. History is replete with the devastating effects of plagues, and the coronavirus disease 2019 (COVID-19) pandemic is a defining global health crisis of our time. Although the development of effective vaccines has saved many lives, the basic workings of the immune system are complex and require the development of animal models, such as inbred mice. Indeed, research in mice has been enormously productive, and the tremendous insights gleaned have resulted in many Nobel prizes and other accolades. However, past results are not necessarily a reliable guide to the future, and a notable limitation of animal models has been their failure to accurately model some human diseases and their inability to predict human immune responses in many cases. With regard to inbred mice, which have been the principal model of choice for immunology, this is likely due to the compromises that were necessary to create a more tractable and reproducible system for experimentation, such as genetic uniformity and lack of pathogen exposure, as well as the fact that mice are evolutionarily quite distinct. These considerations suggest that direct studies of the human immune system are likely to be extremely rewarding, both from a scientific and a medical perspective.

In the past decade there has been an explosion of new approaches and technologies to explore the human immune system with unprecedented precision. Insights into the human immune response to vaccination, cancers, and viral infections such as COVID-19 have come from high-throughput omics technologies that measure the behavior of genes, mRNA (single-cell transcriptomics), proteins (proteomics), metabolites (metabolomics), cells (mass cytometry), and epigenetic modifications (ATAC-seq), coupled with computational approaches.

Sydney Brenner remarked in 2008, We dont have to look for a model organism anymore. Because we are the model organisms. We propose that studying the immune system in humans, who are genetically diverse and afflicted by a multitude of diseases, offers both a direct link to medicine (i.e., translation) and the very real prospect of discovering fundamentally new human biology. New approaches and technology are now making this area much more approachable, but profiling immunity in humans is but the first step. Computational mining of the data and biological validation in animal models or human organoids are essential next steps, in an iterative cycle that seeks to bridge fundamental and applied science, as well as mouse and human immunology, in a seamless continuum of scientific discovery and translational medicine. This will represent a new paradigm for accelerating the development of vaccines and therapeutics.

Systems biology techniques can be used to probe the human immune response to viral infections and can define molecular signatures that predict disease severity and illuminate the underlying mechanisms of disease.

Although the development of effective vaccines has saved countless lives from infectious diseases, the basic workings of the human immune system are complex and have required the development of animal models, such as inbred mice, to define mechanisms of immunity. More recently, new strategies and technologies have been developed to directly explore the human immune system with unprecedented precision. We discuss how these approaches are advancing our mechanistic understanding of human immunology and are facilitating the development of vaccines and therapeutics for infection, autoimmune diseases, and cancer.

See original here:
The science and medicine of human immunology - Science Magazine

Posted in Cell Medicine | Comments Off on The science and medicine of human immunology – Science Magazine

Mapping the Human Heart, Cell by Cell – Howard Hughes Medical Institute

Posted: September 27, 2020 at 4:53 am

Scientists have mapped and described the function of cells in six regions of the adult heart, providing a new foundation for studying heart disease.

Ka-thump. Ka-thump. Ka-thump. Though we barely notice it most of the time, the steady beating of a human heart is an amazingly complex performance. Like an orchestra, thousands of cells have to master their individual performances as well as work together.

Now a team of scientists has created the first atlas of human heart cells, a collection of maps showing nearly half a million heart cells and identifying the role of each in the hearts symphony. The researchers examined six regions in 14 healthy donor hearts, creating a detailed database that provides a new basis of comparison for studying heart disease, the leading cause of death worldwide.

To understand whats going wrong in various forms of heart disease, first we need to know what is normal, says Howard Hughes Medical Institute Investigator Christine Seidman, a cardiovascular geneticist at Harvard University and director of the Cardiovascular Genetics Center at Brigham and Womens Hospital. Seidman and colleagues describe the new heart atlas September 24, 2020, in the journal Nature.

I can summarize my thoughts in one word: monumental, says cardiologist Douglas Mann of Washington University School of Medicine in St. Louis, who was not involved in the study. I think its a really big accomplishment and will be a tremendous source of reference for the field.

Heart cells have proven particularly difficult to study. Unlike some cancer cells and other tissues, there are no heart cells that can be grown indefinitely in the laboratory and studied. Instead, much cardiac research is done using mice, whose hearts have important differences from human hearts.

And healthy human hearts can be hard to find (most are used in transplants). Seidmans team relied on those unusual instances in which healthy hearts were rejected for transplantation and could be frozen for use in research. First, the researchers used a high-throughput sequencing method to define individual characteristics of every heart cell. They then mapped those cells in six regions of 14 human hearts, seven from men and seven from women. For the first time, we have a zip code for each cell to know what population it belongs to, Seidman says.

The team also analyzed heart cells RNA levels using fluorescent markers to glean molecular details of their function. Identifying not only where cells are, but which proteins theyre producing, will be a particular boon for research, Mann says. For instance, by comparing cells in diseased hearts to those in healthy hearts using the atlas, researchers might pinpoint differences and target new therapies for heart disease.

For the first time, we have a zip code for each cell to know what population it belongs to.

Christine Seidman, HHMI Investigator at Brigham and Women's Hospital

Though the researchers studied a relatively small group of hearts (fourteen people cannot replicate the worlds population, Seidman says), the new atlas revealed some biological surprises. The team found previously unknown cell diversity in various parts of the heart. They also uncovered differences between the healthy hearts of males and females; females had a greater proportion of heart muscle cells, called cardiomyocytes, than males. That warrants more research, Seidman says, as those cells might hold clues to differences in heart disease between the sexes.

Still, what we see is striking heterogeneity in terms of the diverse cell types that we now know make up the tissue of the human heart, and in terms of the regional differences within the heart, says cardiologist Hugh Watkins of Oxford University in England, who was not part of the study team. Its certainly a much more complicated organ than many might have imagined!

The atlas is part of the Human Cell Atlas initiative, an effort funded by the Chan Zuckerberg Initiative to map all the cell types in the human body. It takes a big village to do this, Seidman says. Her group worked with an international team of experts on everything from heart surgery to computational biology in order to create the database atlas. All of the data are available at http://www.heartcellatlas.org.

Next, Seidman and her colleagues hope to expand the atlas to a more diverse population (the initial hearts were all from white donors). They are also beginning to compare the proteins made in healthy heart cells to those affected by heart disease.

In due course, what we really want to know is how the different cell types fit together at the microscopic and functional level, Watkins says. Thats another ambitious goal, but the atlas provided here is an exciting start.

###

Citation

Monika Litviukov et al. Cells of the adult human heart. Nature. Published online September 24, 2020. doi: 10.1038/s41586-020-2797-4

Link:
Mapping the Human Heart, Cell by Cell - Howard Hughes Medical Institute

Posted in Cell Medicine | Comments Off on Mapping the Human Heart, Cell by Cell – Howard Hughes Medical Institute

New vaccine strategy harnesses ‘foot soldier’ T-cells to provide protection against influenza – University of Wisconsin-Madison

Posted: September 27, 2020 at 4:53 am

As Americans begin pulling up their sleeves for an annual flu vaccine, researchers at the University of WisconsinMadison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza.

In a study published in Cell Reports Medicine today (Sept. 22), scientists describe a T-cell-based vaccine strategy that is effective against multiple strains of influenza virus. The experimental vaccine, administered through the nose, delivered long-lasting, multi-pronged protection in the lungs of mice by rallying T-cells, specialist white blood cells that quickly eliminate viral invaders through an immune response.

This three-dimensional, semi-transparent rendering of a whole influenza virus shows both the clover-like surface proteins on the outside of the virus, as well as the internal ribonucleoproteins on the inside. Existing influenza vaccines introduce proteins found on the surface of flu viruses to help induce immune protection. A new study by researchers at the UW School of Veterinary Medicine uses an internal nucleoprotein to stimulate the immune system in an effort to create a universal flu vaccine. Centers for Disease Control and Prevention

The research suggests a potential strategy for developing a universal flu vaccine, so you dont have to make a new vaccine every year, explains Marulasiddappa Suresh, a professor of immunology in the School of Veterinary Medicine who led the research. The findings also aid understanding of how to induce and maintain T-cell immunity in the respiratory tract, a knowledge gap that has constrained the development of immunization strategies. The researchers believe the same approach can be applied to several other respiratory pathogens, including the novel coronavirus that causes COVID-19.

We dont currently have any vaccine for humans on the market that can be given into the mucosa and stimulate T-cell immunity like this, says Suresh, a veterinarian with specialty training in studying T-cell responses to viral infections.

The strategy addresses the Achilles heel of flu vaccines, which is to achieve specific antibody responses to different circulating influenza strains annually, by harnessing T-cell immunity against multiple strains. In particular, the new approach calls into action tissue-resident memory T-cells, or TRM cells, which reside in the airways and lining of lung epithelial cells and combat invading pathogens. Like elite soldiers, TRM cells serve as front line defense against infection.

Marulasiddappa Suresh

We didnt previously know how to elicit these tissue-resident memory cells with a safe protein vaccine, but we now have a strategy to stimulate them in the lungs that will protect against influenza, explains Suresh. As soon as a cell gets infected, these memory cells will kill the infected cells and the infection will be stopped in its tracks before it goes further.

Flu vaccines work by arming the immune system with an enhanced ability to recognize and fight off the flu virus. Vaccines introduce proteins found on the surface of flu viruses, prompting the immune system to produce antibodies that are primed to react should the virus attack.

However, because strains must be predicted ahead of flu season in order to produce vaccines, the vaccine in any given year may not completely match the viral strains in circulation that season. Flu viruses frequently mutate and can differ across time and from region to region. In addition, protection is neither long-lasting nor universal.

Even though current vaccines that people get annually stimulate antibody responses, these antibodies dont cross-protect, notes Suresh. If there is a new flu strain not found in that years vaccine, the antibodies that we generated last year wont be able to protect. Thats when pandemics happen because there is a completely new strain for which we have no antibodies. That is a really big problem in the field.

The vaccine developed by Suresh and his team is directed against an internal protein of influenza specifically, nucleoprotein. This protein is conserved between flu strains, meaning its genetic sequences are similar across different strains of flu.

The vaccine also utilizes a special combination of ingredients, or adjuvants, that enhance an immune response, which the researchers developed to stimulate protective T-cells in the lungs. These adjuvants spur T-cells to form into different subtypes in the case of the experimental flu vaccine, memory helper T-cells and killer T-cells. By doing so, the vaccine leverages multiple modes of immunity.

Killer T-cells hunt down and kill influenza virus-infected cells. Helper T-cells assist killer T-cells and produce molecules to promote influenza control. In laboratory studies, the team found that both T-cell types were needed to protect against flu.

Researchers demonstrated in a mouse model of influenza that the vaccine provides long-lasting immunity at least 400 days after vaccination against multiple flu strains. They will next test the vaccine in ferrets and nonhuman primates, two animal models of influenza research more biologically similar to human infection and transmission.

The vaccines combination of adjuvants makes it adaptable to other pathogens and expands the toolbox for vaccine research, notes Suresh. He and his team have devised ways to program immunity to target multiple respiratory viruses. They are currently testing the same vaccine strategy against tuberculosis, which infects more than 10 million people globally each year, and human respiratory syncytial virus, or RSV, a major cause of lower respiratory tract infections during infancy and childhood.

The researchers believe the same vaccine technology can applied against SARS-CoV-2, the coronavirus that causes COVID-19. Based on the COVID-19 immunology, we know this vaccine strategy would most likely work, says Suresh.

The team is now developing an experimental vaccine against COVID-19 and conducting laboratory tests to measure its effectiveness in mice and hamsters, animal models for COVID-19. Initial unpublished studies in mice show that the vaccine stimulates strong T-cell immunity against COVID-19 in the lungs.

Along with its adaptability, this vaccine approach may harbor important safety benefits. Typically, long-lasting T-cell immune responses are stimulated by live vaccines. For instance, the measles, mumps and chickenpox vaccines administered worldwide are live, replicating vaccines essentially benign versions of the pathogenic organism. These live vaccines stimulate strong, almost lifelong immunity. However, they cant typically be given to pregnant or immunocompromised individuals due to health risks.

In the case of the UWMadison teams vaccine, because it is a protein vaccine and not a live vaccine, it should be safe for delivery to those who are pregnant or immunocompromised an advantage in delivering protection to a wider patient population. Suresh says that in recent years, vaccine development efforts have shifted away from live vaccines toward protein vaccines because an increasing number of people are living with compromised immune systems due to chemotherapy, radiation treatments or conditions such as HIV/AIDS.

Previously, we didnt know how to induce T-cell immunity in the lung without live viruses, says Suresh. If we cleverly use a combination adjuvant, which we have developed, you can induce T-cell immunity that should stay in the lungs and protect longer.

THIS WORK WAS supported by THE NATIONAL INSTITUTES of HEALTH (GRANT UO1124299).

Originally posted here:
New vaccine strategy harnesses 'foot soldier' T-cells to provide protection against influenza - University of Wisconsin-Madison

Posted in Cell Medicine | Comments Off on New vaccine strategy harnesses ‘foot soldier’ T-cells to provide protection against influenza – University of Wisconsin-Madison

New research finds statins associated with severity of Covid-19 disease – The Indian Express

Posted: September 27, 2020 at 4:53 am

By: Explained Desk | New Delhi | Updated: September 27, 2020 7:47:46 amThis electron microscope image shows novel coronavirus SARS-CoV-2 virus particles, orange, isolated from a patient. (NIAID/National Institutes of Health via AP)

Statins are a widely used medication for lowering cholesterol. Recent research from US San Diego (University of California at San Diego) School of Medicine associated statins with reduced risk of developing severe Covid-19 disease, as well as faster recovery times.

Now another research team, also from UC San Diego School of Medicine, has explained why this happens. The first study is published in The EMBO Journal, and the new one in the American Journal of Cardiology. In short, statins remove cholesterol from cell membranes, which in turn prevents the coronavirus from getting in.

We know that SARS-CoV-2, the virus that causes Covid-19,enters the human cell by using a protein known as ACE2 on the cell surface. ACE2 can be affected by prescription statins.

Researchers retrospectively analysed the electronic medical records of 170 patients with Covid-19 and 5,281 Covid-negative control patients hospitalised at UC San Diego Health between February and June 2020. Among the patients with Covid-19, 27 per cent were taking statins on admission.

Statin use was associated with a more than 50 per cent lower risk of developing severe Covid-19. Patients taking statins also recovered faster than those not taking statins.

Source: UC San Diego Heath

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Here is the original post:
New research finds statins associated with severity of Covid-19 disease - The Indian Express

Posted in Cell Medicine | Comments Off on New research finds statins associated with severity of Covid-19 disease – The Indian Express

Research on Epigenetics Instrument Market (impact of COVID-19) 2020-2026: Diagenode (Belgium), Thermo Fisher (US), QIAGEN (Netherlands), Illumina (US)…

Posted: September 25, 2020 at 8:58 pm

The Epigenetics Instrument market report will provide one with overall market analysis, statistics, and every minute data relating to the Epigenetics Instrument market necessary for forecasting its revenue, factors propelling & hampering its growth, key market players Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), Bio-Rad (US), and much more. In addition, the key focus points of the report are services, analytics, billings, management, and system.

To get detailed information about the report feel free to contact us @ https://spiremarketresearch.com/report/global-epigenetics-instrument-market-142867#request-sample

Scope: The report offers a statistical analysis of every market aspect that would assist our clients in outlining business strategies and decision-making. Further, it will also aid them to jot down the future interest and accordingly execute their plans.

COVID 19 Impact on Epigenetics Instrument Market: Since the COVID-19 infection flare-up in December 2019, the illness has spread to just about 100 nations around the world with the World Health Organization pronouncing it a general wellbeing crisis. The worldwide effects of the COVID illness 2019 (COVID-19) are as of now beginning to be felt, and will altogether influence the Epigenetics Instrument market in 2020.

Coronavirus can influence the worldwide economy in three primary manners: by straightforwardly influencing creation and request, by making gracefully chain and market interruption, and by its monetary effect on firms and budgetary business sectors.

The episode of COVID-19 has welcomed consequences for some perspectives, similar to flight abrogations; travel boycotts and isolates; cafs shut; all indoor occasions limited; more than forty nations highly sensitive situation pronounced; huge easing back of the flexible chain; financial exchange unpredictability; falling business certainty, developing frenzy among the populace, and vulnerability about future.

Browse Full Report @ https://spiremarketresearch.com/report/global-epigenetics-instrument-market-142867

Details to look for in the report:The Epigenetics Instrument market report entails a market synopsis and offers a definition & outline of the Epigenetics Instrument market. The information provided in the report cover over-the-board data such as market trends, drivers, restraints, opportunities, market shares, challenges, economy, supply chain, and finance in addition to specifics such as software, and communication. Furthermore, the Epigenetics Instrument market is categorized based application(Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other), end-user, technology, the types of product/service(Next-generation Sequencers, qPCR Instruments, Mass Spectrometers, Sonicators, Other), and others, as well as regions North America, Europe, China, Japan, India, Southeast Asia, Other regions (Central & South America, Middle East & Africa, ROW). Additionally, the report encompasses the computed expected CAGR of the Epigenetics Instrument market derived from previous records about the Epigenetics Instrument market and existing market trends together with future developments. The report also highlights other market factors like consumption, asset tracking, and security.

To summarize, the report entails: Overall market summary Growth factors (drivers & restraints) Segmentation Regional analysis Revenue Market players Latest trends and opportunities

Whos at the helm:The team here entails proficient market researchers, knowledgeable consultants, and trustworthy data providers. The team employs proprietary data resources and a number of tools and methods such as NEST, PESTLE, Porters Five Forces, and so on to collect and evaluate the market statistics and other relevant data. Also, the team works round the clock to incessantly update and revise the market data in order to mirror the up-to-the-minute data and trends.

Inquiry to get customization on report @ https://spiremarketresearch.com/report/global-epigenetics-instrument-market-142867#inquiry-for-buying

All in allTo conclude, the Epigenetics Instrument market report will provide the clients with a high-yielding market analysis assisting them to understand the market status and come up with new market avenues to capture hold of the market share.

Read the original:
Research on Epigenetics Instrument Market (impact of COVID-19) 2020-2026: Diagenode (Belgium), Thermo Fisher (US), QIAGEN (Netherlands), Illumina (US)...

Posted in Epigenetics | Comments Off on Research on Epigenetics Instrument Market (impact of COVID-19) 2020-2026: Diagenode (Belgium), Thermo Fisher (US), QIAGEN (Netherlands), Illumina (US)…

Evolution is evolving: 13 ways we must rethink the theory of nature – New Scientist

Posted: September 25, 2020 at 8:58 pm

Do species really exist? Are genes destiny? Do only the fittest survive? Can we shape or stop evolution? New insights into nature are providing surprising answers, and a glorious new picture of lifes complexity

By Michael Le Page , Colin Barras , Richard Webb , Kate Douglas and Carrie Arnold

Our modern conception of evolution started with Charles Darwin and his idea of natural selection survival of the fittest to explain why certain individuals thrive while others fail to leave a legacy. Then came genetics to explain the underlying mechanism: changes in organisms caused by random mutations of genes.

Now this powerful picture is changing once more, as discoveries in genetics, epigenetics, developmental biology and other fields lend a new complexity and richness to our greatest theory of nature. Find out more in this special feature.

The principle of genetic plasticity

IN 1990, an international group of scientists embarked on one of the most ambitious research projects ever undertaken. They would sequence the entire human genome, determining the order of the 3.3 billion base pairs that code for the genes that make the proteins that each of us are built from. There was huge excitement at the prospect of decoding the blueprint of humanity. Given the complexity of our species, our genome was expected to contain at least 100,000 genes. What makes us human would finally be laid bare.

It didnt quite work out like that. The Human Genome Project was a resounding success, publishing its results in 2003, two years ahead of target. However, it revealed that humans only have around 22,000 genes, which is about the same number as other mammals. Meanwhile, the blueprint itself turned out to be encrypted in ways we are still trying to crack.

The same thing is true of us that is true of every species: our DNA can be expressed in myriad different ways

Visit link:
Evolution is evolving: 13 ways we must rethink the theory of nature - New Scientist

Posted in Epigenetics | Comments Off on Evolution is evolving: 13 ways we must rethink the theory of nature – New Scientist

Page 892«..1020..891892893894..900910..»